Global Search | Novartis

Hide Filters

Showing 2719 results

Press release / Apr 03, 2017

Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)

New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate…
Press release / Apr 18, 2017

Novartis expands development programs for NASH through clinical collaboration with Allergan

Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive form of non-alcoholic fatty liver disease There are…
Press release / Apr 18, 2017

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL

Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL…
Press release / Apr 21, 2017

Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*

Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers Comprehensive…
Press release / Apr 19, 2017

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia

NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard…
Press release / Apr 24, 2017

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada

Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial…
Press release / Apr 24, 2017

Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS

Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the…
Press release / Apr 25, 2017

Novartis: ventes en progression (tcc1) dans toutes ses divisions; les moteurs de croissance, Cosentyx et Entresto inclus, compensent l'érosion due aux génériques; l'innovation toujours en plein essor

Chiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):…
Press release / Apr 25, 2017

Novartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generika mehr als wettmachen; Innovationsdynamik setzt sich fort

Der Nettoumsatz wächst um 2% (kWk, -1% USD), da die Wachstumstreiber die Einbussen bei Glivec/Gleevec mehr als wettmachen Cosentyx (USD 410 Millionen, +136% kWk) erzielt in allen drei Indikationen…
Press release / Apr 25, 2017

Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued

Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…